Low Molecular Weight Heparin in Recurrent Implantation Failure
Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial
  • Phase

  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    progesterone enoxaparin ...
  • Study Participants

Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.
Study Started
Jan 31
Primary Completion
May 31
Study Completion
May 31
Last Update
Mar 20

Drug low molecular weight heparin (enoxaparine sodium)

1 mg/kg/day subcutaneously in the luteal phase after IVF treatment

Drug crinone 8% gel

routine luteal phase support with progesterone gel

LMWH Experimental

Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone

Control Active Comparator

Women in the control arm are administered routine luteal phase support without the addition of LMWH


Inclusion Criteria:

History of at least two previously failed fresh embryo transfer cycles
All previously failed cycles to be performed in the American Hospital of Istanbul
Female age ≤ 38 years
Fresh ejaculate sperms to be used for ICSI
No hormonal, coagulation, or immunological disorders detected
Normal uterine cavity, as assessed by diagnostic office hysteroscopy or saline infusion sonography
Normal female and male peripheral karyotype
No Results Posted